



# An Introduction to Clinical Pharmaceutics

Alexander T Florence

**(PP)**  
**h**  
Pharmaceutical Press

# Contents

Preface	ix
Introduction	xi
Book outline	xv
About the author	xvii
<b>1 What is clinical pharmaceuticals?</b>	<b>1</b>
Introduction	1
Physical concepts	2
The nature of the dosage form and outcomes	18
Quality of effect	19
Ingredients in dosage forms and their influence on outcomes	22
Conclusion	23
References	24
<b>2 Excipients: Not always inert</b>	<b>27</b>
Introduction	27
Usually but not always inert	27
E-numbers	31
Cross-reactivity	33
Dyes used in lymph node identification	33
Non-ionic surfactants	33
Polyoxyethylene glycols (PEGs)	35
Adjuvants as therapeutic substances	35
Talc as therapeutic agent and excipient	37
Active excipients in multiple therapies	39
Conclusions	39
References	39
<b>3 Thinking chemically</b>	<b>41</b>
Introduction	41
The chemistry of drugs and clinical pharmaceuticals	42

Chemical nomenclature	47
Surface-active drugs	49
Acids and bases	49
Structural similarities between drugs	52
Cross-reactivity	52
Beta-lactam antibiotics and the formation of oligomers	56
The bisphosphonates	57
Hydrophobic and hydrophilic statins	58
Photochemical reactions and photoinduced reactions	59
Chelation and tetracyclines	64
Sugammadex: a cyclodextrin derivative	64
Conclusions	66
References	67
<b>4 Looking at formulations</b>	<b>69</b>
Introduction	69
Protein drugs and formulations	70
Monoclonal antibodies (MAbs)	73
Amphotericin B formulations	74
A doxorubicin formulation: Doxil	78
A propofol formulation: Diprivan	78
Long-acting depot injections	80
Raft-producing oral formulations	83
Etoposide (Vepesid, VP 16 and etoposide phosphate)	84
Paclitaxel	86
Eutectic mixtures of local anaesthetics	87
Ciclosporin (cyclosporin)	87
Lupron Depot; Prostag SR and Prostag 3	90
Zoladex	90
Fluoroquinolone eye drops	91
Ionsys: Iontophoretic transdermal device for fentanyl	93
Parenterals	93
Chloramphenicol	95
Materials used in drug delivery	95
Conclusions	97
References	98
<b>5 Adverse events and formulations and devices</b>	<b>101</b>
Introduction	101
Dosage form type	103
Reactions to impurities	105

Abnormal bioavailability, high or low	114
Testing for adverse effects	114
Nanosystems	116
Conclusions	118
References	119
<b>6 Paediatric, geriatric and special formulations</b>	<b>121</b>
Introduction	121
Extemporaneous formulations	122
Effect of formulation and presentation: a case from the literature	124
Extemporaneous formulations and performance	126
The elderly and their medication	126
Enteral feeding	128
Drug interactions with nutrient formulations	131
Conclusions	131
References	131
<b>7 Generic medicines: Conventional drugs and biologicals</b>	<b>133</b>
Introduction	133
Regulatory statements on generic products	134
Generics: A question of quality	135
Specific conditions and generics	137
Reading and deconstructing the literature on bioequivalence	139
Antiretroviral drugs	139
Bioequivalence of ophthalmic products	141
The case of sevoflurane	141
Generic biologicals (biologics)	144
Conclusions	146
References	148
<b>8 The future: Delivery systems for modern therapeutics</b>	<b>151</b>
Introduction	151
Personalised medicine and medicines	151
Drug delivery and personalised medicines	152
Technologies	155
Nanotechnology	160
Cell-based therapies	165
Gene therapy	168
Conclusions	169
References	169
<b>Index</b>	<b>173</b>